Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Progress for the sake of progress. The bane of biotech/pharma. Chickens will come home to roost.
Negative Nancy traders will employ repetition on this board. This is a long investment, just as ISRG was from the early 2000s.
Titan is trying to industrialize the market, not revolutionize it. The "wow" factor is that it will do the same tasks safely as a robot at a fraction of the costs, on a platform that has a smaller OR footprint. If surgeons are not seeing anything abhorrent here, that's the good news. I'm not saying these things defensively as a walk back of the device.
I would imagine that a pig has less space to work in. If that's accounted for, I'll give Dr. Valvo a pass for fumbling any tasks on a device he's not regularly using. Arms actuate quite well. Needles look like they drive well.
Lighting looks dim, though. Might just be the second camera.
I think it will be hard to judge the overall scope of the device without immersive evidence. This is, after all, a 3D device console. We're trying to make judgments watching 2D abbreviated test videos on our tablets and computers.
I'd volunteer my body for studies if I needed a gall bladder removed.
What anatomy is this? Looks more condensed than a human. Arms look very free to perform tasks. daVinci arms look like they bump into things.
That MST device is terrific because the wireless remote control can supposedly be retrofitted onto any existing laparoscope device. Traditional Laparoscopy needs to go less proprietary. This will be a welcomed solution to free up scrub techs hands and speed up existing procedures. Great device to shave more seconds away. Shouldn't be too expensive, either.
That Golf R is pure stealth. The idea of owning an AWD golf with a roof rack that smokes cars off the line is superb. Best soccer Dad car ever made.
As much as I abhor American engineered cars, I have to believe that the new Z06 is the best bang for the buck on the market right now. Right now I have a not-so-stock but tastefully aftermarketed S2000 and all my MD bosses with their M3's and 911's think I'm a little punk. I really want one of those new Cayman GT4's but evidently this stock won't take off until they show photos of a prototype. That, and medical school is going to be expensive.
One of the podiatrists I work with tracks E46 M3's (plural). Take an awesome I6 car, cut 800 lbs. from it and that's a great performing BMW. M3-5's are great looking balanced cars, have great power, are very practical, but they don't escape the laws of physics. Eventually you realize that they're overweight and just do everything very well, not any one thing best.
At the same RWD price point, you'll be faster off the line and/or nimbler in a Z06, Cayman GTS, or possibly a SC'd GT500, all with enough space for a supermodel and golfbag. The noise will be better, too. Two seats >>> Four seats!
I already have a long position from earlier this year. I'm just curious when they expect to start lithium acquisition and sales.
Titan is fairly discussed at our hospital, but we're pretty close to Columbus, GA so that may have something to do with it. Most of the talk comes from general surgeons.
When should we expect a definitive feasibility study later this year?
Here it goes...
This is typical biotech hush hush to sneak attack the market and avoid challenges from the status quo and regulatory bodies. If there is nothing to report before required quarterlies and milestone announcements, then there's nothing to report. The lack of investor relations is either intentional to keep things under wraps, or there's no evidence of wrongdoing. Pick your poison, but don't preemptively accuse management. They've got a feasibility prototype, a new endpiece partnership, and are lining up trial locations...and Q4 isn't near yet. Better times are soon for this stock.
If people want weekly announcements and seeking alpha articles, then go buy a silver or software stock where FDA and the ISRG revolving door is nonexistent.
I believe albemarle lithium is mostly in Chile, and Silver Peak has been in production forever. Musk wants Tesla to be American sourced, so there's room for more players, especially near Nevada.
Venture capital is funds in exchange for equity. Venture debt is a set amount of lended funds in exchange for returned principle + interest. There's other negotiable terms as well, like the ability to purchase equity at discount rates, warrants, etc.
Venture capital vs. venture debt generally indicates how the lender is interested in the company. If they believe that the company is a home run, they'll offer the former. If they are looking to diversify their investment, then they may hedge their risk by offer the latter.
Looks like that 100k was filled.
Remote surgery does matter. It all figures back into the notion of getting the surgeon comfortably out of scrubs. The distance is a key figure in this market.
A better lay definition of robotics is the removal of direct drive. Console robotics, Honda's ASIMO, and a remote toy car are examples of robots. An automobile or Surgibot have the user directly driving the unit. You *must* be present to operate the unit.
But from the text it appears that the signal was not encrypted. There's plenty of opportunities in healthcare to cause violence--changing infusion rates, entering dangerous medication orders, etc. but it can be made difficult enough to be a poor use of time for some hacker. I suppose this would be a good way to eliminate one's political opposition.
Or as I've seen before, a rival gang will barge in to the OR and finish off the guy they failed to eliminate earlier.
I was born in the 80s. Save Ferris, L&S. That is all I have to say about that.
I think it is simply to avoid hitting the wall in our OR. In our room, bed head is at 6 o'clock , OR door at 8 o'clock , da vinci at 11 o'clock. We are docking from the patient's right in supine, so bed head rotates to 3 o'clock rather than driving the robot around.
Stressful turning the bed for anesthesia, too. We have to turn our beds 90 degrees for gall bladders. Would Titan's smaller footprint allow for docking from foot of bed? Either way it will be easier to roll around to the side. This is more of an issue with our room design, not with robotics in general.
So there's a large instrument company out there that wants to put up the initial capital to uniquely fit their instruments and set up an assembly line for this supposedly secretive robot company. Sounds like they're believers, too.
I can see those effectors making pyeloplasties easier.
$15-$20 if they accept $1.00-$1.50. That's what I'd offer if I had the capital. You're essentially paying for all the research time and investment done up to this point, plus your spec on future returns, then comparing that to if you just started your own robot program from scratch now. Is Titan the "head start" you want to buy?
Barring any surprising negative news to share, there's only two scenarios to why there's a lack of price action and PR.
1) JH wants to keep the price low to attract a buyer. There's no need to run the price up now and get warrants exercised if time is still on our side until later this year. Based on the timeline any buyer knows PPS is hovering in 52-wk limbo so there's no need to make an offer soon, either.
2) IP strategy. There's no need to reveal your hole cards in this game.
I know everyone wants to see volume and a rise in PPS, especially if there are traders on here, but the conditions don't merit such. I want this company to be successful but there is no need to force things. It feels unhealthy checking this stock daily.
SA articles by disclosed pro-TRXC author didn't help the price action for anyone today anyways. There's a rocky road for all biotech this next year given the threat of a major market correction. There's also campaign season coming up.
I'm still long on TITXF but I won't be adding to my position anytime soon. I still think it is the product that can help industrialize what "first to the market" ISRG brought. It all still comes down to *time=cost*. Whether it is ISRG, TITXF, or TRXC, all this tech increases procedure and OR times with only questionable patient benefit over previous tech. Some procedures more, some less. I feel our hospital took a huge step this year in austerity measures, and I think that's the theme across the country. We want fancy tech but it isn't coming without tradeoffs.
My money will be going elsewhere, likely reinvesting overseas in Mongolia commodities again or waiting for a good entry point into AVGR after its bloated IPO.
Anesthesia here. Plenty of goodies to give LTG that would keep him off the board. Lidocaine jelly after the cialis. Prolong the process.
Titan is the only thing in the green today on my watch list. Things will pick up when the market has calmed down.
Just...just go away please. You're incendiary even during good news. Go back to the TRXC board, please. We know your downplay agenda and it is more annoying than anything on this board.
...and not have to wear a bladder catheter!
My father is a pilot and we often discuss the similarities between the noisy metal box he works in versus the cold meat locker we work in. Try flying a jetliner standing up for 3 hours straight and get back to me how ergonomic and healthy it is to do that...four times a day. That's bedside surgery. That's why surgeons want to sit down in comfortable gear. That's what console robotics offer.
Source? Biggest disadvantage of robotic surgery is not whether or not you're in field. Most surveys I've seen is time of procedure.
They want to sit down. They can make the resident, PA, or scrub tech remained scrubbed in the sterile field. If robotics was about staying in the field, ISRG would not have become what it is now.
Surgibot is revolutionary versus traditional laparoscopic surgery, but from an ergonomic standpoint, it is a step backward from ISRG.
Terrific news. Good land is a good foundation.
There are lots of unknowns in mgmt, but the premise of TRXC's technology is inferior to that of Titan. That's the black and white of it. The rest is grey.
We've started regularly doing single-site gall bladders at our facility with a da vinci Si. We've been having a lot of arm-knocking issues through the single port from my anesthesia perspective. The hysterectomies have generally gone well. Needless to say, our surgeons really want a single-arm instrument like SPORT asap, especially down in our same-day outpatient clinic where the machine can flip between rooms.
"Attendant"...lol. Please go post your drivel elsewhere. Modern surgery requires a minimum of four -- Surgeon, Anesthesia, non-sterile Circulator, sterile Technician. Neither SPORT nor Surgibot will eliminate the Technician responsibilities. There's too much that goes on in preparing an operating room as well as too many things that can go wrong with any equipment.
This guy wants the surgeon to operate a Surgibot while lifting the uterus up.
I share the same sentiments. SPORT is the future of console surgical robotics in terms of mobility and industrialization.
Now if we can just design a robot that does all our documentation and dictations, we're set to take care of patients.